Nieuws

ONCODRONE Receives €2.5 Million EUROSTARS Grant

Oncodrone, the anti-cancer company based in Nijmegen, The Netherlands, has been granted a € 2,5 million Eurostars grant for the development of its lead drug OCD155 for treatment of prostate cancer.
ONCODRONE Receives €2.5 Million EUROSTARS Grant

MIT Arrangement: ICT company OpenNovations

“Met mijn ict-bedrijf OpenNovations doen we veel zaken voor de sector Life Sciences. We helpen onder meer laboratoria op het vlak van data-uitwisseling om in veilige digitale omgevingen samen te kunnen werken. Op dit vlak ben ik bezig met de ontwikkeling van een innovatief concept waarbij de integriteit van data in alle stadia wordt gewaarborgd en gecontroleerd. Hiervoor zou de MIT ons goed op weg kunnen helpen”, zegt Hans de Raad van OpenNovations.
MIT Arrangement: ICT company OpenNovations

SkylineDx appoints Leonard Kruimer as CFO Peter Schineller as CCO

SkylineDx, a molecular diagnostics company developing and commercializing innovative, gene signature-based diagnostics, announces the appointment of Leonard Kruimer as Chief Financial Officer per August 15th and Peter Schineller as Chief Commercial Officer per August 1st.
SkylineDx appoints Leonard Kruimer as CFO Peter Schineller as CCO

New medication: shorter time to market

De ‘time to market’ voor nieuwe medicijnen kan ruim één jaar korter. Patiënten kunnen zo sneller over nieuwe geneesmiddelen beschikken. Actal, het Adviescollege toetsing regeldruk, adviseert de minister van Volksgezondheid, Welzijn en Sport om de onnodige belemmeringen in Europese en nationale regelgeving en in de uitvoeringspraktijk weg te nemen.
New medication: shorter time to market

The Netherlands #1 European Health System according to Health Consumer Powerhouse

In 2014 the Dutch health care system is awarded, for a third time in a row, as best European health care system in the annual research of think tank Health Consumer Powerhouse (HCP). With a resounding score of 898 out of a possible 1000 points our country set an all-time record. An achievement to be proud of!
The Netherlands #1 European Health System according to Health Consumer Powerhouse

FICHe eHealth accelerator enters final phase with 20 companies

The FICHe eHealth accelerator has announced the 20 companies that will enter the third and final phase of the program. The final phase will be a 7-month mentorship period and each company will receive up to € 152.000 in working capital.
FICHe eHealth accelerator enters final phase with 20 companies

Opportunities at K-Hospital Event South Korea

Van 10 tot 13 september wordt in Goyang (Zuid-Korea) de K-Hospital fair gehouden. Het event focust zich op de ziekenhuisindustrie, waarbij onder andere medische apparatuur, ziekenhuisbouw, medicijnen, wearable devices, ziekenhuis solutions en medische IT technologie centraal staan. De organisatie van het K-Hospital event is geïnteresseerd in Nederlandse bedrijven die actief zijn in de simulation & serious gaming industrie. De interesse gaat uit naar de Nederlandse expertise in serious en applied games voor arts training, ouderenzorg en revalidatie.
Opportunities at K-Hospital Event South Korea

Rockstart Digital Health Accelerator Programme

Are you building a digital health company and are you passionate about making a sustainable impact on people’s health? Join our Digital Health Accelerator program where we help you build, validate and scale your digital health startup and find the best international product/market fit.
Rockstart Digital Health Accelerator Programme

Development and Time Schedule Knowledge and Innovation Contract

From this week on the Top Team and bureau will start the development of the Knowledge and Innovation Contract 2016-2017. Read more on the time schedule and contact information.
Development and Time Schedule Knowledge and Innovation Contract

Cristal Therapeutics and PX Biosolutions to Develop Vaccines Based on CriVac® Nanotech Platform

Cristal Therapeutics, a privately-held life sciences company developing innovative products against cancer and other diseases, by using its patented nanotechnology platforms, announced the start of a collaboration with PX Biosolutions (Melbourne, Australia). The joint research and development is focussed on the application of Cristal Therapeutics’ vaccine technology CriVac® for the design of innovative vaccines.
Cristal Therapeutics and PX Biosolutions to Develop Vaccines Based on CriVac® Nanotech Platform